ROCKVILLE, Md., Nov. 14, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. The offering is subject to market […]
— Completed Enrollment of Phase 2b Proof-of-Concept Clinical Trial for the Prevention of C. difficile Infection (CDI), Antibiotic-Associated Diarrhea (AAD) and the Emergence of Antibiotic-Resistant Organisms — — Awarded Research Contract from Centers for Disease Control and Prevention to Determine SYN-004’s (ribaxamase) Ability to Prevent Antibiotic-Resistance in the Gut Microbiome — — Conference Call Today,
— Conference Call Scheduled for Tuesday, November 1, 2016 at 8:30 a.m. EDT — ROCKVILLE, Md., Oct. 25, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, announced today that the Company intends to release its operational highlights and financial results for the quarter ended
— Funding to Support Ongoing Phase 2b Study to Determine SYN-004’s (ribaxamase) Ability to Prevent the Emergence of Antibiotic-Resistance in the Gut Microbiome of Study Participants — ROCKVILLE, Md., Oct. 6, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific
— Top-line Results Anticipated in the First Quarter of 2017 — ROCKVILLE, Md., Sept. 20, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases, announced today that following the completion of a previously planned interim analysis by an
– Held End of Phase 2 Meeting with FDA and Received Guidance for Advancement to First Pivotal Trial for SYN-010, for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) – – Company Provides Update on Enrollment for Phase 2b Proof-of-Concept Clinical Trial for SYN-004 (ribaxamase), for the Prevention of C. Difficile Infection (CDI) and
— FDA Provides Company with Recommendation and Guidance for Clinical Study Design for Phase 2b/3 Adaptive Trial — ROCKVILLE, Md., Aug. 2, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases, announced today the completion of an End of
— Conference Call Scheduled for Wednesday, August 3, 2016 at 4:30 p.m. EDT — ROCKVILLE, Md., July 26, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its operational highlights and financial results for the three and six
— First Granted Patent in Europe Directly Related to Ribaxamase, intended to Prevent C. difficile Infection, Antibiotic-Associated Diarrhea and the Emergence of Antibiotic-Resistant Organisms — ROCKVILLE, Md., July 12, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome announced today that the European Patent
— Ribaxamase Designed for the Prevention of C. difficile Infection, Antibiotic-Associated Diarrhea & the Emergence of Antibiotic-Resistant Organisms — — Oral Presentation Planned for ANAEROBE 2016 — ROCKVILLE, Md., July 7, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific
